Navigation Links
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
Date:4/29/2010

statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from Ortho-McNeil-Janssen Pharmaceuticals, Inc. and/or Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Ortho-McNeil-Janssen Pharmaceuticals, Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
2. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
5. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
6. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
7. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
8. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
11. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Merck (NYSE: MRK ), known as MSD outside ... , is teaming with celebrity chef and cookbook author Leticia ... an educational program encouraging Hispanics with type 2 diabetes to achieve ... to help reduce the risk of serious health problems. Hispanics in ... risk for developing type 2 diabetes than non-Hispanic white adults, and ...
(Date:9/19/2014)... -- UBM Medica US announces that  OncoTherapy ... oncologists and other clinicians gain a better understanding of ... therapies and immunotherapies, discusses some of the latest news ... Every September, Blood Cancer Awareness Month is ... cancers—helping to increase survival rates and improve the quality ...
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
... Calif., Oct. 20 VisionCare Ophthalmic Technologies, Inc., ... individuals with age-related macular degeneration (AMD), today announced ... telescope technology. VisionCare,s investigational telescope implant is the ... approval by the FDA Ophthalmic Devices Advisory Panel ...
... AlphaDetail, an innovator in pharmaceutical marketing research, is pleased ... tracking services: AlphaLink and AlphaMonitor. , AlphaLink helps clients ... with tracking study results. "One of the biggest issues ... data, gathered from a number of different sources," says ...
Cached Medicine Technology:VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings 2VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings 3AlphaDetail Tracking Study Enhancements: The Advantage of Integration and Speed 2
(Date:9/19/2014)... U.S. military troops deployed to sunny climates may have ... new study. Many returning troops reported getting ... military personnel developed blisters on their skin or noticed ... their moles since being deployed overseas. All of ... the study authors noted. "The past decade of ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... Ariz. (Sept. 19, 2014) - New research published today ... new Ebola cases could reach 6,800 in West Africa ... measures are not enacted. , Arizona State University ... that the rate of rise in cases significantly increased ... that a mass quarantine was put in place, indicating ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Famous Vancouver ... announced that it has now become a one-stop-solution for ... and businesses in Vancouver. The company has achieved this ... services to its customers. While there are many companies ... to have a single vendor who can offer all ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2
... Vomiting syndrome made him a recluse at times, researcher ... Australian researcher claims he has identified the illness that ... vomiting, headaches and skin problems for most of his ... been suggested for the illness that could be so ...
... gender differences that explain the aging inequity , ... yet another gender inequity: Women develop more and deeper ... do. , The disadvantage had long been suspected, but ... Foad Nahai, a plastic surgeon practicing in Atlanta and ...
... ... of nimotuzumab , ... (PRWEB) December 17, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma ... signing of an agreement under which Therapure Biopharma will provide aseptic fill and finish ...
... 17 Over the last few weeks there has been an ... e cigarette opposition in an attempt to scare the population concerning ... when the evidence clearly shows that the product is indeed a ... opinions from top medial and harm reduction specialist around the world. ...
... , , SAN DIEGO, Dec. 17 CareFusion ... been notified of an unsolicited mini-tender offer by TRC Capital Corporation ... stock, representing approximately 1.8 percent of the shares of common stock ... below the share closing price of CareFusion common stock on Dec. ...
... , , HOUSTON, ... Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin ... for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic ... late-stage development - the rights to which have been ...
Cached Medicine News:Health News:New Theory Emerges on Darwin's Illness 2Health News:Mouth Area Wrinkles More in Women Than Men 2Health News:Mouth Area Wrinkles More in Women Than Men 3Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 2Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 3Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 4Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 3Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 4
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: